In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bellicum Pharmaceuticals Inc.

www.bellicum.com

Latest From Bellicum Pharmaceuticals Inc.

CAR-T Forecast: Celgene Follows, But Also Leads As Next Batch Of T-Cell Therapies Near Market

Celgene's lead program will be the third autologous CD19-targeting T-cell therapy on the market, but the company is in the lead among BCMA-targeting CAR-T candidates. Next-generation technologies are also on the way.

ImmunoOncology Research and Development Strategies

ASH Preview: Practice-Changing Darzalex And Imbruvica, Advances In Beta-Thalassemia And More

Late-breaker presentations for Darzalex in multiple myeloma and Imbruvica in CLL will showcase "practice-changing" results in front-line settings. Other highlights include new treatments for beta-thalassemia, such as Acceleron's and Celgene's luspatercept.

Clinical Trials Cancer

Finance Watch: In Obesity, Vivus Raises Cash For Deals, Orexigen Finds A Buyer

Public Company Edition: Strategies diverge in obesity as Vivus restructures debt and raises cash for a new deal and new focus, after Orexigen nears a sale of the company via bankruptcy court. Also, Clovis leads recent offerings, while layoffs are on the table at Catabasis.

Financing Business Strategies

Pipeline Watch: Phase III Starts With Oxabact, Imeglimin And Favipiravir

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

 

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Immune Disorders
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Bellicum Pharmaceuticals Inc.
  • Senior Management
  • Rick Fair, Pres. & CEO
    Atabak Mokari, CFO
    David M Spencer, PhD, CTO
    Gregory Naeve, PhD, CBO
    William Grossman, MD, PhD, CMO
  • Contact Info
  • Bellicum Pharmaceuticals Inc.
    Phone: (832) 384-1100
    2130 West Holcombe Blvd.
    Ste. 800
    Houston, TX 77030
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register